ERBB3 and adenosarcoma: In our cohort of adenosarcomas, we detected alterations in PI3K pathway in 26% (5/19) of cases (PIK3CA, PIK3CG, PIK3R1, PTEN mutations and/or amplification of AKT2 or ERBB3).